Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

doi:10.1200/JCO.2013.54.5392

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2014

von Pawel Joachim, Jotte Robert, Spigel David R, O'Brien Mary E R, Socinski Mark A, Mezger Jörg, Steins Martin, Bosquée Léon, Bubis Jeffrey, Nackaerts Kristiaan, Trigo José M, Clingan Philip, Schütte Wolfgang, Lorigan Paul, Reck Martin, Domine Manuel, Shepherd Frances A, Li Shaoyi, Renschler Markus F

Abstract excerpt

PURPOSE: Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III trial compared the safety and efficacy of amrubicin versus topotecan as second-line treatment for SCLC. PATIENTS AND METHODS: A total of 637 patients with refractory or sensitive SCLC were randomly assigned at a ratio of 2:1 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to NAD(P)H Dehydrogenase (Quinone)

Share to Odds Ratio

Share to Proportional Hazards Models

Share to Small Cell Lung Carcinoma

Source

Open in PubMed

Identifiers

PMID: 25385727
DOI: 10.1200/JCO.2013.54.5392

Genes

NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.PMID 25385727Read ↗

A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.Semantic proximity Read ↗

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.Semantic proximity Read ↗

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

A phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesotheliomaSemantic proximity Read ↗

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.Semantic proximity Read ↗

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA ExpressionSemantic proximity Read ↗

Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation.Semantic proximity Read ↗

Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.Semantic proximity Read ↗

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.Semantic proximity Read ↗

Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.